TMCnet14d
Fresenius Kabi Receives FDA 510(k) Clearance for Adaptive Nomogram, Enhancing Plasma Collection Efficiency with the Aurora Xi Plasmapheresis System
Plasma-derived therapies are essential for treating a wide range of conditions, including immune deficiencies, bleeding ...
Contract Pharma14d
FDA Grants 510(k) Clearance for Fresenius Kabi’s Adaptive Nomogram
The U.S. Food and Drug Administration (FDA) has granted 510 (k) clearance for Fresenius Kabi’s Adaptive Nomogram, an alternate algorithm that will be available in the Aurora Xi Plasmapheresis System ...
pharmaphorum2d
EU has its first RoActemra biosimilar, from Fresenius Kabi
The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi. The biosimilar of IL-6 inhibitor ...